Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 114, Issue -, Pages 79-101Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2017.05.011
Keywords
Cancer immunotherapy; Checkpoint blockade; Adoptive cell therapy; Nanoparticles
Categories
Funding
- Ragon Institute of MIT
- MGH
- Harvard
- NIH [CA206218, CA172164, CA174795]
- Stand Up To Cancer
Ask authors/readers for more resources
Cancer immunotherapy is now a powerful clinical reality, with a steady progression of new drug approvals and a massive pipeline of additional treatments in clinical and preclinical development. However, modulation of the immune system can be a double-edged sword: Drugs that activate immune effectors are prone to serious nonspecific systemic inflammation and autoimmune side effects. Drug delivery technologies have an important role to play in harnessing the power of immune therapeutics while avoiding on-target/off-tumor toxicities. Here we review mechanisms of toxicity for clinically-relevant immunotherapeutics, and discuss approaches based in drug delivery technology to enhance the safety and potency of these treatments. These include strategies to merge drug delivery with adoptive cellular therapies, targeting immunotherapies to tumors or select immune cells, and localizing therapeutics intratumorally. Rational design employing lessons learned from the drug delivery and nanomedicine fields has the potential to facilitate immunotherapy reaching its full potential. (C) 2017 The Authors. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available